Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: A PET study in schizophrenia

American Journal of Psychiatry

Volumn 164, Issue 4, 2007, Pages 630-637

  Mizrahi, Romina ^b   Rusjan, Pablo ^b   Agid, Ofer ^b   Graff, Ariel ^b   Mamo, David C ^b   Zipursky, Robert B ^b   Kapur, Shitij ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; ISOREMOXIPRIDE; ISOREMOXIPRIDE C 11; NEUROLEPTIC AGENT; OLANZAPINE; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; RISPERIDONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BINDING AFFINITY; BRAIN REGION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MOTOR DYSFUNCTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TREATMENT DURATION;

EID: 34247533866     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.4.630     Document Type: Article

References (39)

1. Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:1081-1090
2. Marder SR: Subjective experiences on antipsychotic medications: synthesis and conclusions. Acta Psychiatr Scand Suppl 2005; 427:43-46
3. Hollister LE: Complications from the use of tranquilizing drugs. N Engl J Med 1957; 257:170-177
4. Voruganti L, Awad AG: Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 2004; 171:121-132
5. Verhoeff NP, Kapur S, Hussey D, Lee M, Christensen B, Psych C, Papatheodorou G, Zipursky RB: A simple method to measure baseline occupancy of neostriatal dopamine D2 receptors by dopamine in vivo in healthy subjects. Neuropsychopharmacology 2001; 25:213-223
6. Verhoeff NP, Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L, Rui Q, Zipursky RB, Kapur S: Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav 2003; 74:425-432
7. Voruganti L, Slomka P, Zabel P, Costa G, So A, Mattar A, Awad AG: Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging. Neuropsychopharmacology 2001; 25:642-650
8. de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, Linszen D: Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry 2004; 49: 290-296
9. de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PM, Linszen D: Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry 2003; 160:303-309
10. Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS: Typical antipsychotic drugs - D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002; 56:31-36
11. Hall H, Farde L, Halldin C, Hurd YL, Pauli S, Sedvall G: Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 1996; 23: 115-123
12. Nieoullon A, Coquerel A: Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol 2003; 16(suppl 2):S3-S9
13. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ, Gacinovic S, Kerwin RW, Pilowsky LS: Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000; 150:132-140
14. Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B, Paillere-Martinot ML: Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 2001; 179:503-508
15. Wise RA: Dopamine, learning and motivation. Nature Reviews Neuroscience 2004; 5:483-494
16. Pilowsky LS: Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl Med Commun 2001; 22: 829-833
17. Olsson H, Halldin C, Swahn CG, Farde L: Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 1999; 19:1164-1173
18. Olsson H, Farde L: Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy: a simulation study based on experimental data. Neuroimage 2001; 14:936-945
19. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B: Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50:79-88
20. Houle SKS, Hussey D, Jones C, Dasilva J, Wilson AA: Quantification of Brain Function Using PET. Edited by Myers RCV, Bailey D, Jones T. London, Academic Press Inc, 1996, pp 262-265
21. Bremner JD, Bronen RA, De Erasquin G, Vermetten E, Staib LH, Ng CK, Soufer R, Charney DS, Innis RB: Development and reliability of a method for using magnetic resonance imaging for the definition of regions of interest for positron emission tomography. Clin Positron Imaging 1998; 1:145-159
22. Lammertsma AA, Hume SP: Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4(3, pt 1):153-158
23. de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J: Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry 2000; 157:1019-1020
24. Olsson H, Halldin C, Farde L: Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 2004; 22:794-803
25. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D(2)/D(3) receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005; 30:2283-2289
26. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes TR, Mukherjee J: D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006; 85(1-3): 232-244
27. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L: Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003; 6:361-370
28. Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA, Anderson GM, Seibyl JP, Innis RB: Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000; 387:179-188
29. Mesulam MM, Mufson EJ: Insula of the old world monkey, I: architectonics in the insulo-orbito-temporal component of the paralimbic brain. J Comp Neurol 1982; 212:1-22
30. Deutch AY, Lewis DA, Whitehead RE, Elsworth JD, Iadarola MJ, Redmond DE Jr, Roth RH: Effects of D2 dopamine receptor antagonists on Fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse 1996; 23:182-191
31. Wise RA: Brain reward circuitry: insights from unsensed incentives. Neuron 2002; 36:229-240
32. Arnt J, Skarsfeldt T, Hyttel J: Differentiation of classical and novel antipsychotics using animal models. Int Clin Psychopharmacol 1997; 12(suppl 1):S9-S17
33. Brady AL, Olmstead RE, London ED, Farahi J, Meyer JH, Grossman P, Lee GS, Huang J, Hahn EL, Mandelkern MA: Smoking-induced ventral striatum dopamine release. Am J Psychiatry 2004; 161:1211-1218
34. Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, Diksic M, Tremblay RE, Dagher A: Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 2003; 49:226-231
35. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA: Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001; 49:81-96
36. Camus A, Javoy-Agid F, Dubois A, Scatton B: Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine. Brain Res 1986; 375:135-149
37. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT: Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156:675-682
38. Craig AD: Human feelings: why are some more aware than others? Trends Cogn Sci 2004; 8:239-241
39. Tamminga CA, Carlsson A: Partial dopamine agonists and dopaminergic stabilizers in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002; 1:141-147